1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
604C5F628D94FDFD185257C91005A9AA8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-strategic-kol-management-coordination-software-and-thought-leader-identification?opendocument
18
19opendocument
203.80.4.76
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Thought Leader Services

Strategic KOL Management: Coordination, Software and Thought Leader Identification

ID: 5296


Features:

8 Info Graphics

12 Data Graphics

100+ Metrics

6 Narratives


Pages/Slides: 27


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Strategic KOL Management: Coordination, Software and Thought Leader Identification"

STUDY OVERVIEW

In the face of changes in the regulatory and access landscape, pharmaceutical organizations can no longer afford to have multiple functions and regions blindly contacting the same Key Opinion Leader (KOL). For any number of reasons – efficiency and courtesy are two obvious ones – organizations should have a KOL management system that ensures coordinated interactions. An organization's CRM software clearly plays a role in this.


Best Practices, LLC conducted this research to help organizations create and maintain a strategic KOL management system. In particular, this study examines current approaches to coordination, software and thought leader identification for a strategic KOL management system. This study provides an evidence-based understanding of current and evolving approaches to creating and maintaining an integrated, strategically-focused KOL management system.

KEY TOPICS

  • Coordinating and Communicating Strategic Thought Leader Management and Engagement
  • Aligning Software Tools to Support Strategic Thought Leader Management and Engagement
  • Identifying and Engaging Thought Leaders
KEY METRICS
  • Functional areas that conduct strategic KOL management activities (across indicated product lifecycle periods)
  • Most effective approaches to coordination of KOL management activities
  • Communication channels your organization uses to share best practices across the organization
  • Frequency of nonfield-based strategic KOL management staff interactions with KOLs
  • Software programs/systems utilized by your organization
  • Do you utilize a system with a global line of sight for all KOL activities
  • Involvement level of MSLs in KOL identification
  • Importance rating of 8 KOL services
  • KOL activities most valued by organization
SAMPLE KEY FINDING
  • Respondents recognized the importance having a platform for sharing learning/best practices among the staff involved in strategic KOL management. Almost half of respondents said they use quarterly in-person meetings while nearly a third utilize an online database/spreadsheet.

METHODOLOGY

Thirty-four TL management leaders from 29 biopharma and device organizations participated in the external field survey, and we interviewed 4 participants for in-depth insights

Industries Profiled:
Health Care; Pharmaceutical; Biotech; Medical Device; Manufacturing; Education; Science; Biopharmaceutical; Clinical Research; Laboratories; Medical


Companies Profiled:
Abbott Nutrition; Abbvie; Amgen; Antibiotice; Astellas; Baxter Healthcare; Biogen Idec; Boehringer Ingelheim; Crescendo Bioscience; Cubist Pharmaceuticals; Eisai; Intermune; Janssen; Jazz Pharmaceuticals; Mallinckrodt; Marcyrl; Medtronic; Merck; MSD; Onyx Pharmaceuticals; Pierre Fabre Medicament; ProStrakan; Reliance Institute of Life Sciences; Roche; Sanofi; Sanofi Renal; Servier; Shire; TauRx Therapeutics; Janssen Biotech; Inc.; A.P. Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.